View Older Stories View More Recent Stories

Jan 6, 2026 07:01AM Genprex reports preclinical data for diabetes gene therapy GPX-002
Jan 6, 2026 07:00AM Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Nov 24, 2025 07:00AM Genprex publishes phase 1 lung cancer gene therapy trial data
Nov 24, 2025 07:00AM Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Nov 19, 2025 07:00AM Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Nov 18, 2025 07:00AM Genprex receives US patent for cancer gene therapy combination through 2037
Nov 18, 2025 07:00AM Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Nov 4, 2025 07:02AM GENPREX receives European patent intent for cancer gene therapy combination
Nov 4, 2025 07:00AM Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Oct 28, 2025 07:00AM GENPREX collaborators present preclinical data for lung cancer therapy
Oct 28, 2025 07:00AM Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets an
Oct 23, 2025 07:02AM Genprex collaborators to present lung cancer gene therapy data at conference
Oct 23, 2025 07:00AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Target
Oct 14, 2025 07:00AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Target
Sep 2, 2025 08:30AM Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Aug 18, 2025 09:29AM Genprex receives patent allowances for Reqorsa cancer therapy combinations
Aug 18, 2025 09:29AM Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Aug 4, 2025 08:31AM Genprex issues stockholder letter with 2025 corporate update
Aug 4, 2025 08:30AM Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Jun 24, 2025 09:25AM Genprex (GNPX) Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy
Jun 24, 2025 09:25AM Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 23, 2025 09:00AM Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 3, 2025 07:00AM Genprex to Participate at BIO 2025 International Convention
May 29, 2025 07:00AM Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
May 28, 2025 07:00AM Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
May 7, 2025 07:00AM Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
May 6, 2025 07:00AM Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
Apr 30, 2025 07:30AM Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Apr 29, 2025 07:30AM Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Apr 28, 2025 07:30AM Genprex (GNPX) Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Apr 28, 2025 07:30AM Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Apr 24, 2025 08:15AM Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Apr 22, 2025 08:15AM Genprex (GNPX) Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Apr 22, 2025 08:15AM Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Mar 26, 2025 08:16AM Genprex (GNPX) Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy
Mar 26, 2025 08:15AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Mar 25, 2025 08:15AM Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Mar 4, 2025 08:15AM Genprex to Participate at BIO Europe Spring 2025
Feb 19, 2025 08:16AM Genprex (GNPX) Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Feb 19, 2025 08:15AM Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Feb 18, 2025 08:16AM Genprex (GNPX) Provides Update on Diabetes Gene Therapy Program
Feb 18, 2025 08:15AM Genprex Provides Update on Diabetes Gene Therapy Program
Feb 13, 2025 08:15AM Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Jan 23, 2025 08:00AM Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Jan 6, 2025 09:15AM Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 16, 2024 09:15AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cel
Dec 16, 2024 09:15AM Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung
Nov 20, 2024 09:29AM Genprex (GNPX) Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
Nov 20, 2024 09:29AM Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
Nov 5, 2024 09:30AM Genprex (GNPX) Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy
View More Recent Stories View Older Stories